查找临床试验
已按「多发性骨髓瘤」检索，对应国际通用词 multiple myeloma
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 10:14，每 5 分钟自动同步IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
China
年龄 18 Years – 80 Years
The First Hospital of Jilin University
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
China
年龄 18 Years – 75 Years
Chongqing Precision Biotech Co., Ltd
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
United States、China、Israel、Japan
年龄 18 Years – 不限
AbbVie
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
China
年龄 18 Years – 不限
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
China
年龄 18 Years – 75 Years
Shanxi Bethune Hospital
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
United States、Argentina、Australia、Belgium、Brazil 等 12 国
年龄 18 Years – 不限
Pfizer
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
China
年龄 18 Years – 70 Years
Institute of Hematology & Blood Diseases Hospital, China
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
United States、Belgium、Canada、France、Italy 等 12 国
年龄 12 Years – 不限
Sumitomo Pharma America, Inc.
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
China
年龄 18 Years – 不限
Shanghai Changzheng Hospital
A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
China
年龄 18 Years – 75 Years
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
United States、Argentina、Australia、Austria、Belgium 等 12 国
年龄 18 Years – 不限
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company